FDA Finds Liver Risk In Generic Graves' Treatment

Law360, New York (June 3, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration issued a warning Wednesday cautioning health care professionals that use of generic anti-thyroid drug propylthiouracil to treat hyperthyroidism and Graves’ disease has been linked to serious liver injury in recent studies.

Recent reports to the FDA’s Adverse Event Reporting System showed an increased risk of serious liver injury, including liver failure and death, in connection with adult and child use of PTU compared with the use of first-line Graves’ disease drug methimazole, the agency said.

The FDA cautioned physicians to...
To view the full article, register now.